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HFAILURE TO ERADICATE HIV DESPITE FULLY SUCCESSFUL HAART INITIATED
IN THE FIRST DAYS OF LIFE
ALESSANDRA VIGANÒ, MD, DARIA TRABATTONI, PHD, LAURA SCHNEIDER, MD, FRANCESCO OTTAVIANI, MD, ANTONIA ALIFFI, MD,
ERIKA LONGHI, PHD, STEFANO RUSCONI, MD, AND MARIO CLERICI, MD
Highly active antiretroviral therapy (HAART) started shortly after birth resulted in reversion of human immunodeficiency
irus (HIV) plasma viremia, proviral DNA in PBMC, viral culture, and serum HIV antibodies to negative. Discontinuation of
AART 2 years after apparent HIV eradication, however, was followed by virus replication, CD4 decline, and destruction of
IV-specific lymphocytes, epitomizing the impossibility of HIV eradication. (J Pediatr 2006;148:389-91)
n vertical human immunodeficiency virus (HIV) infection, the first months after birth are characterized by rapid plasma viral
turnover and extremely high HIV plasma viremia.1 Because HIV viral load is predictive of subsequent disease course, and
disease progression is accelerated in HIV-infected children,2 early, potent combination therapy regimens could provide the
est opportunity to control viral replication and to preserve the immune system. Data in adults showing that initiation of
ntiviral therapy during acute infection (or even before seroconversion) can result in control of viral replication even after
herapy is interrupted 3 further strengthen this suggestion. We report the case of a child in whom this hypothesis was
ested.
CASE REPORT
The patient was a female, born by cesarean delivery at 38 weeks gestation to a mother who had seroconversion for HIV
weeks earlier. HIV testing was performed because the husband was newly diagnosed to be infected with HIV. Maternal CD4
ounts and HIV RNA at week 37 were 987/L and 139,000 copies/mL, respectively. Intrapartum and peripartum prophylaxis
as performed with zidovudine (2 mg/kg bolus intravenously, followed by 1 mg/kg/h
ntil the end of the cesarean procedure)  nevirapine (200 mg once) in the mother, and
idovudine orally (2 mg/kg every 6 hours) in the newborn. Virologic analyses were
erformed on the newborn within 48 hours of birth: qualitative HIV-RNA was positive,
nd HIV plasma viremia was 15,300 copies/mL. Antiviral therapy with zidovudine (150
g/m2/d)  lamivudine (4 mg/kg/d)  nevirapine (160 mg/m2/d) was initiated within 1
eek after birth; therapy led to full suppression of HIV plasma viremia (50 copies/mL)
nd stabilization of the CD4 counts and of the CD4/CD8 ratio (Table). Serum HIV-
pecific antibodies and HIV-DNA polymerase chain reaction (PCR) were undetectable
8 months after initiation of therapy; this result was confirmed 3 times during the
ollow-up period. After 23 months of HAART, HIV proviral DNA-PCR in PBMC was
ssessed for gag and env regions in 10 replicates (ie, 10 different PCR tests). HIV-1
roviral genome was investigated by a nested PCR. Primers were designed on the HXB2
enome sequence spanning the V3 loop and gag region. HIV viral cultures were per-
ormed at the same time, following standard methods. Results were negative. A bilateral
onsillectomy was performed at the same time; histologic study of the tonsils was normal,
nd tonsillar proviral HIV-1 DNA (GeneAmplimer HIV-1; Applied Biosystems, Foster
ity, CA) was negative. Functional immunologic analyses were performed as well at this
ime and showed a strong gag- and env-specific proliferative response, a high percentage
f circulating gag- and env-specific interleukin-2 and interferon (IFN) gamma-producing
D4 T lymphocytes, and a minimal amount of activated T cells (Figure). On the basis
f these results, the antiviral therapy was stopped. Within 1 month, the CD4 count
ropped from 3674 to 2174/mL, and HIV plasma viremia rose to 46,850 copies/mL. This
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3as accompanied by drastic reduction of HIV-specific pro-
iferation (Figure, panel A), of gag- and env-specific, IL-2 and
FN gamma-producing CD4 T lymphocytes (Figure, panel
and C), and of naïve T lymphocytes (panel D), and by a
ignificant increase of memory cells (Figure, panel E and F),
s well of activated T cells (panel G). Influenza A virus-
pecific (FLU) proliferation and cytokine production was not
ffected. The patient did not restart therapy; this decision was
aken by the family. At the last visit (June 2005) the child was
ymptom free; HIV RNA was 15,261 copies/mL, and the
able. Virologic and immunologic test results from b
onths of age
Birth 1 Month 6
D4 count (cell/mm3) NT1 3531
D4:CD8 ratio NT 2.40
IV RNA (copies/mL) 15300 50
erum HIV-specific Ab  N.T.
NT  Not tested.
igure. Immunologic analyses in child examined 2 years after initiation of
est results to negative. A, Proliferative response by peripheral blood monon
FLU) and phytohemagglutinin (PHA). B, Antigen-stimulated, IL-2–produ
ymphocytes; D, CD4 and CD8  T lymphocytes and CD4 naive (CD
ymphocytes. E, CD4 central memory (CM) and effector memory (EM) T
ymphocytes. G, Activation markers. All analyses were performed at interru
ases background was subtracted.D4 count was 1400, with a CD4 percentage of 24%. m
90 Viganò et alDISCUSSION
The promptness with which therapy was initiated, the
eversion of all virologic tests to negativity, the absence of HIV
n accessible lymphatic sites, the disappearance of serum HIV-
pecific antibodies, and normalcy of clinical features led us to
elieve that eradication might have been achieved in this child.
oon after interruption of HAART, however, HIV viremia
ebounded, CD4 counts declined, HIV-specific and naïve T
ymphocytes and central memory T lymphocytes dropped, and
to discontinuation of antiretroviral therapy at 24
ths 12 Months 18 Months 24 Months
3240 3176 2461
3.00 1.08 2.05
50 50 50
  
RT within days of birth and after reversion of all clinical and virologic
cells stimulated with HIV antigens (gag and env), influenza A virus
D4 T lymphocytes. C, Antigen-stimulated, IFN-producing CD4 T
/CD62l/CCR7), as well as CD8 naive (45RA/CCR7) T
phocytes. F, CD8 central memory (CM), and effector memory (EM) T
of HAART (20 Dec 2003) and 1 month thereafter (20 Dec 2004). In allirth
Mon
5872
2.50
50
HAA
uclear
cing C
45RA
lym
ptionarkers of lymphocyte-activation significantly increased.
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IThe detection of HIV-specific T helper lymphocytes
uring antiviral therapy, however, may have been a clue that
IV was replicating in some sanctuary, inaccessible even by B
ymphocytes. In fact, repeated observations have demon-
trated that the magnitude and the breadth of HIV-specific
mmune response wanes within months after cessation of
xposure to the virus in uninfected newborns of HIV-sero-
ositive women.4,5 On the other hand, the immunologic
esults could have further reinforced the possibility of eradi-
ation, as in this patient: (1) gag-specific T helper responses
ere strong, and these responses have repeatedly been asso-
iated with immunologic control of HIV infection6; and (2)
mmune activation, an unfavorable prognostic factor, was not
etected.
Perinatal exposure to high antigenic loads can lead to
olerance. This phenomenon could explain the lack of immu-
ologic control seen in this child, but it is unlikely given that
IV-specific responses were detected. Lack of cytotoxic T
ymphocytes (CTL) maturation and function stemming from
xposure to a suboptimal antigen load or from a direct effect
f the antiviral therapy also could justify these results. This
as not examined. The low HIV-specific CD8 lymphocyte
esponses frequently detected in vertically-infected young in-
ants7 and lack of CTL activity could lead to the infant’s
nability to contain the replication of HIV hidden in reser-
oirs. Within 1 month of therapy interruption HIV-specific
mmune responses disappeared, whereas influenza-specific T
ymphocytes were not affected. In spite of 2 years of complete
emission of HIV virologic parameter, virus-specific immune J
ailure To Eradicate HIV Despite Fully Successful HAART
nitiated In The First Days Of Lifeesponses in less than 30 days after cessation of therapy. The
esson that can be drawn from this case is that the ability of
IV to hide and persist, even in the face of a prompt
herapeutic intervention immediately after birth and of the
isappearance of virus-specific serum antibodies, is remark-
bly potent.
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